COMMUNIQUÉS West-GlobeNewswire

Phonak AI-Powered Hearing Aids Recognized with 2026 Artificial Intelligence Excellence Awards
24/03/2026
Phonak Virto R Infinio and Phonak Infinio Ultra Sphere honored for advancing real-world hearing performance through AI innovation STÄFA, Switzerland, March 24, 2026 (GLOBE NEWSWIRE) -- Phonak , a global leader in [...]
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse
24/03/2026
Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse L’approbation chez les patients atteints d’une forme [...]
Idorsia announces the nomination of three candidates for election to the Board of Directors
24/03/2026
Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting 2026 on May 6, 2026 All Board members – current and [...]
Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire »
24/03/2026
Mise en ligne du document «Q1 2026 aide-mémoire » Paris, France – 24 mars 2026 . Sanofi annonce la mise en ligne de son « Q1 2026 aide-mémoire » sur la page « Investisseurs » de son site internet. Résultats du premier [...]
Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
24/03/2026
Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures Proceeds will [...]
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
24/03/2026
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, [...]
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
24/03/2026
Focused on selective acquisitions of high-quality companies in strategic industrial sectors MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge 1 , a strategic [...]
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
24/03/2026
NESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL) today announced the pricing of an underwritten offering of 459,112 ordinary shares (the “Shares”) at a [...]
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
23/03/2026
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million [...]
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
23/03/2026
SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class [...]
Globus Medical Announces Board Departure
23/03/2026
AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the [...]
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
23/03/2026
Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral [...]
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/03/2026
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, [...]
Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026
23/03/2026
Conference call today, March 23, 2026, at 4:30 PM ET SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended [...]
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
23/03/2026
Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease Wednesday, April 1: Animal and in vitro studies on TNX-801 (horsepox, [...]
Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis
23/03/2026
AURA Phase 2 clinical trial designed to evaluate the safety and efficacy of AP02 compared to placebo in patients with idiopathic pulmonary fibrosis (IPF) BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Avalyn, a clinical- [...]
Inventiva annonce la publication et la présentation de ses résultats financiers annuels 2025
23/03/2026
Daix (France), New York ( États-Unis ), le 23 mars 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale [...]
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
23/03/2026
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of [...]
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
23/03/2026
Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice [...]

Pages